Early treatment consideration in patients with hepatitis B ‘e’ antigen-positive chronic infection: is it time for a paradigm shift?
Series: Viruses ; Vol. 4 (5)Basel SWI MDPI 2022Description: 12pSubject(s): Online resources: Summary: To date, antiviral therapy has been reserved for patients with ostensibly active liver disease, fibrosis or cirrhosis, and/or increased risk of HCC. Historically, patients with hepatitis B ‘e’ antigen (HBeAg)-positive chronic infection, were not offered antiviral therapy. The current review discusses the reasons to consider early antiviral therapy in HBeAg-positive chronic infection. Related terms Hep B, HBV.Item type | Current library | Call number | Status | Date due | Barcode | |
---|---|---|---|---|---|---|
Online journal/article | Library Online | Available |
Available in: English
To date, antiviral therapy has been reserved for patients with ostensibly active liver disease, fibrosis or cirrhosis, and/or increased risk of HCC. Historically, patients with hepatitis B ‘e’ antigen (HBeAg)-positive chronic infection, were not offered antiviral therapy. The current review discusses the reasons to consider early antiviral therapy in HBeAg-positive chronic infection.
Related terms Hep B, HBV.